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Abstract
Background: Gluten-free diet (GFD) decreases the quality of life of celiac disease (CD) patients, who frequently ask
to occasionally ingest gluten-containing food. We evaluated CD patients reporting voluntary and occasional
transgressions to their GFD.
Methods: From October 2017 to September 2018, the patients reporting occasional and voluntary gluten ingestion
(GFD-noncompliant) were prospectively enrolled. These patients underwent clinical examination, blood tests,
duodenal biopsy, capsule enteroscopy (CE), and a validated food-frequency questionnaire (FFQ) assessing the
frequency and quantity of gluten intake. Mortality was calculated and compared to the general population. A
group of patients on strict GFD (GFD-adherent) acted as controls.
Results: One thousand three hundred seventy-eight CD patients were evaluated during the study period. One
hundred nine (8%) reported occasional (weekly or monthly) voluntary ingestion of gluten. The mean gluten intake
was 185.2 ± 336.9 g/year, and the duration of their incorrect GFD was 8.6 ± 6.9 years. Among the noncompliant
patients, 57% did not present any histological alteration; furthermore, the Marsh score profile was not different
between compliant and noncompliant patients. Seventy percent did not present any alteration at CE. Seventy-five
percent of patients reported no gastrointestinal symptoms after gluten ingestion. Twenty-three percent of patients
in the GFD-noncompliant group presented positive tTG-IgA. No association was found between gluten intake,
clinical symptoms, and biomarkers. Mortality was not different between the groups and the general population.
Conclusions: Our results are that in a real-life scenario, a group of CD patients on long-term gluten intake showed
no significant clinical symptoms or small bowel damage, thus suggesting that a degree of tolerance towards gluten
consumption can be reached.
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Background
Celiac disease (CD) affects approximately 1% of the
population worldwide [1] and is defined as an auto-
immune enteropathy triggered by the ingestion of gluten
proteins derived from wheat, rye, and barley [2]. CD is
characterized by an impaired immune response in genet-
ically susceptible individuals (carrying the HLA DQ2
and/or DQ8 haplotypes) and leads to the inflammation
and atrophy of the small bowel (SB) mucosa [2]. As a
consequence, the classical clinical picture of CD is char-
acterized by nutrient malabsorption with several signs of
malnutrition, but extra-intestinal symptoms and associ-
ation with other autoimmune disorders are frequently
present as signs of systemic disease [3, 4].
Nowadays, CD is considered a permanent condition of
immunological intolerance to gluten, which requires strict
lifelong gluten-free diet (GFD) [3]. The withdrawal of glu-
ten from a patient’s diet usually results in the recovery of
his/her intestinal mucosa with an improvement of symp-
toms, SB absorption, and normalization of the circulating
autoantibody (anti-type 2 transglutaminase IgA, TG2) [5].
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It is not clear which of these targets should be considered
as the primary or secondary endpoint of GFD for CD pa-
tients towards their long-term prognosis [6]. Although
safe and efficient, GFD is very restrictive, resulting as a
burden on social life and quality of life (for both patients
and caregivers) [7–10] and frequently with poor compli-
ance [11–13]. Moreover, the clinical response to inadvert-
ent or voluntary gluten ingestion by treated CD patients
can be very heterogeneous, ranging from gastroenteritis-
like pictures to no symptoms [3, 14]. Consequently, pa-
tients’ motivation or understanding in the following strict
GFD is often poor. Moreover, it is not known if the prog-
nosis of patients can be made worse by occasional gluten
ingestion, especially in patients without symptoms [15].
This issue is crucial in clinical practice for the man-
agement of those CD patients that report occasional in-
gestion of gluten and whose number can reach up to
30% of cases [16].
Recent data has demonstrated that several CD patients
can abandon GFD and maintain a healthy state with no
adverse events or CD recurrence [17]. A large group of
them will develop intestinal lesions after different expos-
ure periods to gluten consumption, but the fact that
some of them seem to tolerate gluten for long periods is
intriguing [18]. Thus, the actual role of GFD in the pre-
vention of CD-related complications (e.g., refractory dis-
ease, intestinal lymphoma) and other immune disorders
is debated [15, 19].
The present work aimed to evaluate the dietary, clin-
ical, endoscopic, and histological characteristics of pa-
tients with CD reporting occasional and voluntary
transgression to GFD.
Methods
Patients
A prospective study was carried out from October 2017
to September 2018 at the “Center for Prevention and
Diagnosis of Celiac Disease”, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico in Milan (Italy).
CD diagnosis was made according to the national and
international guidelines [20, 21] including positivity to
anti-type 2 transglutaminase IgA (TG2) and the pres-
ence of villous atrophy at duodenal histology, according
to the Marsh-Oberhuber classification [22]. All the sub-
jects referring to the outpatient service were clinically
evaluated by an expert gastroenterologist, and they were
interviewed by a trained nutritionist who evaluated the
adherence of the patients to their GFD. Adherence to
the GFD was evaluated by means of an in-depth inter-
view executed by a nutritionist trained in the treatment
and follow-up of patients affected by gluten-related dis-
orders [23].
The patients were discriminated on the basis of the
voluntary ingestion of gluten-containing food types. The
kind of symptoms (bowel habits, abdominal pain, dys-
pepsia, meteorism, diarrhea, asthenia, constipation,
gastro-esophageal reflux, etc.) arising after gluten inges-
tion was reported, when present. CD patients underwent
upper endoscopy with duodenal biopsies. During gas-
troscopy (Pentax, EG27-i10 gastroscope), at least 4 ori-
ented biopsies from the distal duodenum and 2 from the
bulb were taken using standard endoscopic forceps (Bos-
ton Scientific, Radial Jaw™ 4) and were routinely proc-
essed for hematoxylin-eosin and CD3 staining as
previously described [24]. All the obtained biopsies were
reviewed by a pathologist and classified according to the
Marsh-Oberhuber criteria [22]. Further, capsule entero-
scopy (CE) was carried out after SB cleaning the day be-
fore the procedures with 2 L polyethylene glycol and
overnight fasting. An axial view capsule system (Pillcam
SB3, Medtronic) was used. At the end of the examin-
ation, the data recorded from the capsules were ac-
quired. The recorder was removed after 12 h and the
data downloaded to the dedicated system. CEs were read
by an expert physician reading more than 100 CEs per
year [25]. A suspicion of mucosal atrophy was posed in
the presence of mosaicism, scalloping, granular mucosa,
and/or loss of SB folds.
The histological and serological data from a randomly
selected fully GFD-compliant, TG2 IgA-negative group
of CD patients examined over the same period of time
were used as control data.
The patients who agreed to participate gave their writ-
ten informed consent and were enrolled in the study.
The local Ethics Committee for Human Research of the
City of Milan approved the study protocol (ref. no. 344_
2018).
Evaluation of gluten intake
For the patients reporting voluntary and occasional in-
gestion of gluten-containing food, the gluten consump-
tion was assessed by means of a frequency food
questionnaire (FFQ) validated and modified in the CD
population [26]. FFQ was used to evaluate the frequency
and the quantity of gluten-containing foods consumed
during the last 12 months. A trained nutritionist admin-
istered the questionnaire: information on frequency, type
of meals, and when gluten was consumed was collected.
In addition to specific questions on foods with prede-
fined gluten content, the FFQ also included open ques-
tions to detect and include any eventual (sporadic)
gluten intake.
To understand the dietary source of gluten and which
foods were most frequently consumed, a qualitative ana-
lysis of the diet was carried out; foods were grouped into
five food categories: (a) bread and substitutes, (b) sweets,
(c) beer, (d) pasta and other cereals, and (e) pizza/
focaccia.
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The intake of gluten from each food category was esti-
mated on the basis of conversion factors (8.9 g gluten/
100 g wheat flour, 4.2 g from barley, 3.0 g from rye, and
1.29 from oats) [27]. When analyzing beer consumption,
the gluten content was obtained using a specific conver-
sion factor, 0.00185 mg gluten/ml beer [28].
Mortality
In order to avoid any bias on the mortality rate, death
and causes of death were collected from the Central
Register of Italy’s National Health Service collecting epi-
demiological data on the whole Italian population. The
analysis was carried out on the overall mortality levels
for all causes/pathologies. Comparisons were achieved
using the mortality tables of Lombardy’s population
(from Italy’s National Institute of Statistics, ISTAT). The
SURVSOFT® V.2.0 software was used for the analysis
(Cancer Register Bavaria, URL: http://www.krebsregis-
ter-bayern.de/software_e.html) [17]. The standardized
mortality ratio (SMR) was defined as the ratio of the ob-
served number of deaths in the population being studied
and the expected number of deaths in a comparable
group of individuals from the general population,
matched with respect to the main factors affecting mor-
tality, commonly age, sex, and calendar period.
Statistical analysis
The data are described as mean ± SD or median (inter-
quartile range) unless otherwise indicated. The continu-
ous demographic variables were compared between the
groups using independent Student’s t test. Fisher’s exact
test was used to evaluate the distribution of categorical
variables (i.e., gender distribution, the presence of
gastrointestinal symptoms), the Marsh score between
the groups of adherence to the GFD. STATA® rel. 13.1
(StataCorp, College Station, TX) was used, and statistical
significance was set at 5% α level.
Results
Among the 1378 adult CD subjects [mean age 48 ± 16,
mean age at diagnosis 37 ± 34, 344 (25%) males] referred
to our outpatient service during the study period, 109
(8%) [mean age 45 ± 13, mean age at diagnosis 29 ± 19,
38 (35%) males] reported some voluntary and occasional
ingestion of gluten-containing food. The number of
males was significantly (p = 0.03) higher in the group of
patients referring to voluntary gluten ingestions. No dif-
ferences in age or age at diagnosis were observed. Not-
ably, the mortality of patients reporting some voluntary
occasional ingestion of gluten was significantly lower
when compared to the general population one (SIR 0,
95% CI 0–0.61).
Among the patients reporting voluntary gluten inges-
tion, 48 (44%) patients completed a frequency food
questionnaire (FFQ) to estimate the amount of gluten
ingested per year; 149 patients following a strict GFD
composed the control group (their demographic and
clinical details are reported in Table 1). The complete
study flowchart is provided in Fig. 1. In the GFD-
noncompliant group, the mean amount of gluten
ingested by patients was 185.2 ± 336.9 g/year (0.5 ± 0.9 g/
day) for a mean period of 8.6 ± 6.9 years. The frequency
of voluntary ingestion of gluten by the patients was usu-
ally once a week or month (4% of patients ingested glu-
ten daily, 40% at least once a week, 35% on a monthly
basis, and 21% at least once a year). The description of
the alimentary sources of gluten in noncompliant pa-
tients is shown in Fig. 2. Dietary gluten mainly came
from bread and its substitutes and from pizza/focaccia,
pasta, and cereals. In the considered food groups, there
were no differences in the intake of gluten. Among pa-
tients fulfilling the FFQ, 36 (75%) reported no symptoms
after ingestion of gluten-containing food. In the 12
(25%) patients reporting a symptomatic relapse after vol-
untary gluten ingestion, the symptoms were change in
bowel habits (16%), abdominal pain (25%), constipation
(8%), meteorism (16%), dyspepsia (12%), asthenia (16%),
and gastro-esophageal reflux (25%). This “symptomatic”
group did not present any correlation in terms of tTG-
IgA values or histology.
In the GFD-noncompliant, 22.9% had positive tTG-IgA
values (Table 1). In general, 75 (69%) of noncompliant pa-
tients underwent upper endoscopy with duodenal hist-
ology; notably, 43 (57%) presented an unremarkable
duodenal histology (Marsh 0); 50 (66%) presented normal
or nonatrophic lesions (i.e., Marsh 0, 1, or 2), and 25
(33%) showed signs of atrophy, demonstrating a Marsh
profile similar to the patients of the compliant group.
Again, when only patients fulfilling the FFQ (35) have
been considered, the Marsh score defining the absence of
mucosal damage (Marsh 0) was evidenced in 43 (28.8%)
patients in the GFD-adherent vs. 16 (45.7%) patients in
the GFD-noncompliant group (p = 0.55). The same com-
parison for duodenal atrophy (Marsh 3) showed a 28.8%
in the GFD-adherent compared to the 34.3% in the GFD-
noncompliant group. In Fig. 3a, the different grades of vil-
lous atrophy are reported; no statistical differences have
been found between the compliant and noncompliant
groups. Moreover, no statistical differences were found
when comparing the gluten intake of GFD-noncompliant
patients with or without duodenal histologic damage: the
noncompliant patients with Marsh 0 duodenal histology
consumed 131.4 ± 154.4 g/year, Marsh 1–2 472.7 ± 707.9
g/year, and Marsh 3 187.9 ± 206.0 g/year. More details
about the types of gluten-containing food ingested and
their relationship to duodenal histology are reported in
Fig. 3b. In Fig. 3c and d, two duodenal histologic images
are reported. Moreover, there was no association between
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the frequency of gluten intake and intestinal mucosal
damage (p = 0.896), gastrointestinal symptoms (p = 0.292),
tTG-IgA positivity (p = 0.346), and the extent of the atro-
phic lesion as reported by CE (p = 0.209).
Thirty (62%) noncompliant CD patients underwent
CE, and 21 (70%) turned out unremarkable. In 9 (30%)
cases, endoscopic signs of mucosal atrophy were de-
scribed at CE. The following endoscopic signs of atrophy
have been reported: mosaicism in 3 cases; mosaicism
and scalloping in 3; scalloping and granular mucosa in 1;
mosaicism, scalloping, and granular mucosa in 1; and
granular mucosa in 1 case. The extension of SB atrophy
expressed as the percentage of the SB transit time was
8.0 ± 3.2%. Again, the amount of gluten voluntarily
ingested by patients with an atrophic mucosa at CE vs.
CD patients without atrophy at CE was not statistically
different, being 111.5 ± 159.7 and 211.9 ± 188.8 g gluten
per year, respectively. Considering the presence of atro-
phy at histology as the reference standard (all patients
undergoing CE were histologically evaluated), sensitivity
and specificity of CE were 0.6 (95% CI 0.26–0.88) and
0.85 (95% CI 0.61–0.97), respectively. In Fig. 4a and b,
two examples of CE investigations are represented.
Discussion
Our study has shown that occasional and voluntary diet-
ary gluten intake is not associated with the onset of clin-
ical, serological, histologic, or endoscopic signs of CD
for a group of CD patients. In particular, no association
was found between histological alterations and the
amount of gluten intake after CD diagnosis.
CD is the most common autoimmune enteropathy in
the Western countries, and strict lifelong GFD is consid-
ered the only available treatment, usually inducing
symptomatic remission, mucosal healing, and
normalization of the serological alterations [3]. However,
looking at GFD without a “dogmatic” point of view, a
number of ambiguities and/or questions arise [15]: what
is the prognosis of patients occasionally assuming glu-
ten? What is the value of histology and serology during
follow-up? Can some patients develop any tolerance to
gluten? What is the role of GFD in asymptomatic pa-
tients? As a consequence, the “historical theory” that
strict GFD is necessary for all CD patients and, forever,
is somehow questionable. Furthermore, GFD usually
worsens the quality of life of CD patients, and thus, a
number of patients present a low degree of compliance
Table 1 Characteristics of enrolled patients
GFD-noncompliant (n = 48) GFD-adherent (n = 149) p value
Age, years 45.5 ± 16.2 43.7 ± 12.5 0.357
Gender, M/F 17/31 21/128 0.001
Age at CD diagnosis, years† 30 (6.5–49.2) 33 (25–41) 0.431
Duration of the diet, years 8.6 ± 6.9 5.9 ± 7.6 0.110
Positive anti-transglutaminase antibody, % 22.9 0 0.000
Presence of autoimmune diseases, n (%) 14 (29%) 30 (20%) 0.23
†Data as median (interquartile range)
Fig. 1 Flow chart on the patients participating in the study
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to GFD because of their occasional ingestion of gluten,
for example, during social events [5, 16].
In our cohort of noncompliant CD patients, mainly
composed of asymptomatic patients, voluntary gluten in-
gestion has occurred on a weekly or monthly basis and
has been maintained by the patients over a long period
of time. During such time, those patients have been
followed by our outpatient service on an annual basis
through nutritional counseling, gastroenterological visits,
and hematological and endoscopic investigations. Not-
ably, the mortality of these patients is not different (if
not lower) when compared to the mortality of the gen-
eral population. The results from the studies to date in-
vestigating the mortality risk in CD patients are
conflicting. The major problems in clearly defining such
a risk come from the difficulty to distinguish between di-
agnosed and undiagnosed CD patients, patients with dif-
ferent CD sub-types, and to extrapolate those patients
affected by refractory celiac disease (RCD) from the
population database. RCD, although rare (less than 1%
of CD patients), presents a very high risk of malignant
transformation and consequently a high mortality rate:
the presence of RCD in the analyzed cohorts could
represent a bias in studies investigating mortality in CD
[29, 30]. If some studies showed a fourfold increased
mortality in CD [31, 32], mainly due to lymphoma, without
demonstrating a clear connection with gluten exposure,
often only indirectly suggested [33], other studies have
failed to confirm this scenario [34]. In line with our find-
ings, Olen et al. have analyzed mortality in GFD-compliant
and GFD-noncompliant patients without finding any con-
nections to the development of lymphoma [35].
Looking at the duodenal histology (usually considered
as the reference standard for CD management) of non-
compliant patients compared to the patients following a
strict GFD, the incidence of patients maintaining duo-
denal atrophy was similar in the two groups (roughly
30%) without differences regarding the amount of
ingested gluten between the noncompliant patients pre-
senting or not any duodenal damage. It is well known
that one third of CD patients correctly responding to
GFD retain some sort of duodenal damage at histology
[36]. The clinical significance of this finding is unknown
and controversial. For this reason, it is doubtful if the
duodenal damage found in noncompliant patients is
really induced by gluten ingestion or by chance.
Fig. 2 Gluten intake from the main alimentary groups
Elli et al. BMC Medicine           (2020) 18:42 Page 5 of 8
Moreover, in order to investigate the presence of small
bowel lesions beyond the Treitz ligament, as indicated
by the recent guidelines and meta-analyses [37, 38], CE
has been performed without showing any significant al-
terations but some signs of proximal atrophy in a small
part of patients.
In our cohort of noncompliant patients, only the pres-
ence of circulating tTGA was significantly increased as
compared to compliant controls. However, the tTGA levels
do not correlate with the dose of ingested gluten or with
the frequency of its ingestion. This finding is in line with
earlier studies demonstrating the presence of tTGA in non-
compliant patients, especially during childhood. Again, the
prognostic significance of such peripheral signs in the ab-
sence of symptoms or histologic alterations remains unclear
and not correlated to any malignancy development [30].
Fig. 3 Distribution of patients (35 GFD-noncompliant vs. 149 GFD-adherent), according to the Marsh classification (a) and according to the
sources of gluten (b). c, d Two examples of duodenal histology with CD3 staining of a noncompliant and a compliant patient, presenting a
normal mucosa (Marsh 0) and severe (Marsh 3c) villous atrophy are reported
Fig. 4 Capsule endoscopy investigations presenting atrophic (a) and normal (b) mucosa
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There is evidence supporting the hypothesis that it
would be possible to achieve a certain level of tolerance
to gluten after a variable period depending on each par-
ticular patient. In this regard, the systematic reviews
available to date have focused on determining what can
be considered as the highest safe intake of gluten for CD
patients. Hischenhuber et al. have concluded that the
maximum daily intake of gluten should be between 10
and 100 mg [39]. Other authors have reported that this
limit is highly variable with some patients tolerating an
average of 34–36mg of gluten per day. Although there
is no evidence to determine a single definitive threshold,
a daily gluten intake of < 10mg is unlikely to cause sig-
nificant histological abnormalities in these patients [40].
This daily limit can represent an apparent individual tol-
erance level. It has been supposed that tolerance to glu-
ten can be related to the age at CD diagnosis: individuals
with diagnosis during childhood could develop a greater
degree of tolerance compared to diagnosis at adulthood
[41]. Other reports have demonstrated that some adult
patients diagnosed during childhood did not show clin-
ical or histological relapse after initially consuming diet-
ary gluten [42, 43]. It should be mentioned that these
studies came with methodological considerations mainly
related to the evaluation of serology and histology of
duodenal biopsies but not focusing on what could be the
predictive factors of gluten tolerance. Notably, the stud-
ies investigating gluten tolerance or performing a gluten
challenge administered gluten on a daily basis while the
majority of patients in our study and in real life ingested
gluten sporadically or only during specific events. This
consideration suggests that it is the timing of the as-
sumption (chronic vs. sporadic) more than the quantity
of gluten that can drive a significant immunological and
histological response.
Although our study involved a large number of pa-
tients followed over a long time period, it presents some
points of weakness such as the absence of a randomized
challenge with occasional gluten ingestion and the
mono-centric design. Furthermore, we did not perform
complete evaluations of comorbidities, apart from the
presence of autoimmune diseases that appeared not re-
lated to gluten ingestion. This finding is in line with a
previously published study analyzing the risk factors for
the development of autoimmunity in CD [4].
Conclusions
In summary, our study has shown that a group of celiac
patients with long-term gluten intake shows no signifi-
cant clinical symptoms or histological abnormalities,
suggesting that a degree of tolerance towards gluten
consumption can be reached. A better understanding of
the mechanisms through which some patients can reach
a degree of tolerance to gluten could indeed result in
personalized GFD allowing for the intake of different
amounts of gluten. This achievement can help to im-
prove a patient’s quality of life and diminish the social
burden associated with lifelong GFD.
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